Vivera Appoints Dr. Fabio Macciardi as Neurogenetics Scientific Advisor

NEWPORT Beach, Calif., June 16, 2022 /PRNewswire/ — Vivera Prescribed drugs is delighted to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company’s Biosciences Division. As an professional in neurogenetics, Dr. Macciardi will support Vivera in the research and improvement of targeted genetic therapies to address the unmet requirements of individuals with various central nervous system (CNS) disorders.

Vivera Pharmaceuticals, Inc. Logo (PRNewsfoto/Vivera Pharmaceuticals, Inc.)

Vivera Prescribed drugs, Inc. Brand (PRNewsfoto/Vivera Prescription drugs, Inc.)

“We are honored to welcome Dr. Macciardi to Vivera’s Advisory Board.” –Paul Edalat

“I am looking ahead to signing up for Vivera as we make the most of our expertise of the human mind to develop therapeutic resources for sufferers with neuropsychiatric conditions,” said Dr. Macciardi.

Dr. Macciardi is a Professor of Molecular Psychiatry at the University of California, Irvine (UCI), Faculty of Medication. At this time, he is main investigate targeted on examining the purpose and evolution of neurocognitive genes and their related characteristics making use of next-era DNA and RNA sequencing procedures.

The objective of Dr. Macciardi’s exploration is to detect and characterize the part of non-coding RNAs and transposable aspects (TEs) as epigenetic regulators (factors that can modify gene expression without the need of altering the genetic code alone) in neural tissue and throughout neuropsychiatric ailments. His lab has by now recognized additional than 600,000 expressed discrete TEs in the human brain as significant epigenetic regulators of gene expression in neurogenesis, autism spectrum condition (autism), schizophrenia, and Alzheimer’s sickness.

“We are honored to welcome Dr. Macciardi to Vivera’s Advisory Board,” said Paul Edalat, Chairman and CEO of Vivera. “His research has led to impressive discoveries in the genetics field, and we are wanting ahead to harnessing his skills to aid our investigate and advancement initiatives.”

Furthermore, Dr. Macciardi’s analysis will be specifically instrumental in the Company’s drug development and licensing approach for TABMELT, Vivera’s novel patented and patent-pending sublingual drug shipping program that permits clients to acquire a medication by positioning a pill under the tongue. Making use of his scientific track record, Dr. Macciardi will help Vivera pick out medicines that may perhaps better serve people in a sublingual format.

“I welcome Dr. Macciardi to the staff,” mentioned Gerald A. Maguire, M.D., D.L.F.A.P.A., Vivera’s Main Neurosciences Advisor. “With each other, we will investigate revolutionary methods to treat neuropsychiatric diseases, which could be life-shifting to clients who are affected.”

About Vivera Prescription drugs

Vivera Prescribed drugs is an innovative, science-driven pharmaceutical organization found in Southern California. The Enterprise has worldwide exclusivity to license the patented and patent-pending TABMELT sublingual drug shipping and delivery procedure for pharmaceutical use and holds its possess issued patents on ZICOH, a good dose-controlled electronic professional medical gadget. The Business has also received a Notice of Allowance for its transportable telemedicine station, MDZone. With multiple divisions, like its pharmaceutical, neurosciences, professional medical engineering, biosciences, and highly developed diagnostics divisions, Vivera Prescribed drugs is vertically built-in with patented technological know-how, manufacturing capabilities, and distribution for its items.

For extra information and facts, make sure you visit or join with us on LinkedInFbTwitter, or Instagram

Ashley LeVine
[email protected]



View primary material to down load multimedia:

Supply Vivera Pharmaceuticals, Inc.